Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky

We read with some concern the report by Yokote et al. ([1][1]), in which the authors recommend that LC16m8, a replicating smallpox vaccine licensed in Japan, be considered for use in persons who are immunocompromised. The authors presented new data from mouse models comparing the virulence of LC16m8